Natixis Advisors LLC Sells 77,244 Shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB)

Key Points

• Natixis Advisors LLC reduced its holdings in Genmab A/S by 37.5%, owning 128,525 shares after selling 77,244 shares in the first quarter, with a total value of approximately $2.5 million.
• Several institutional investors have increased their stakes in Genmab A/S, including Two Sigma Investments LP, which boosted its position by 122.2% in the fourth quarter, now holding over 1.7 million shares.
• Analysts have mixed opinions on Genmab A/S, with a consensus rating of "Moderate Buy" and an average price target of $37.80, reflecting optimism despite some cautious ratings.

Natixis Advisors LLC decreased its holdings in shares of Genmab A/S Sponsored ADR (NASDAQ:GMAB - Free Report) by 37.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 128,525 shares of the company's stock after selling 77,244 shares during the quarter. Natixis Advisors LLC's holdings in Genmab A/S were worth $2,516,000 at the end of the most recent quarter.

Several other institutional investors have also recently bought and sold shares of GMAB. Deep Track Capital LP acquired a new position in Genmab A/S during the fourth quarter worth about $41,740,000. Two Sigma Advisers LP raised its stake in Genmab A/S by 168.8% during the fourth quarter. Two Sigma Advisers LP now owns 1,653,500 shares of the company's stock worth $34,509,000 after acquiring an additional 1,038,400 shares in the last quarter. Two Sigma Investments LP raised its stake in Genmab A/S by 122.2% during the fourth quarter. Two Sigma Investments LP now owns 1,706,364 shares of the company's stock worth $35,612,000 after acquiring an additional 938,455 shares in the last quarter. Marshall Wace LLP raised its stake in Genmab A/S by 162.2% during the fourth quarter. Marshall Wace LLP now owns 1,122,296 shares of the company's stock worth $23,422,000 after acquiring an additional 694,243 shares in the last quarter. Finally, Cubist Systematic Strategies LLC acquired a new position in Genmab A/S during the fourth quarter worth about $12,360,000. Institutional investors and hedge funds own 7.07% of the company's stock.

Wall Street Analysts Forecast Growth

GMAB has been the subject of several research analyst reports. Truist Financial boosted their target price on Genmab A/S from $45.00 to $46.00 and gave the stock a "buy" rating in a research note on Tuesday, July 8th. Wall Street Zen raised Genmab A/S from a "hold" rating to a "buy" rating in a research note on Monday, July 28th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating, seven have given a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Genmab A/S has a consensus rating of "Moderate Buy" and an average price target of $37.80.

Genmab A/S Stock Performance

Shares of Genmab A/S stock traded up $0.57 on Tuesday, hitting $21.65. The stock had a trading volume of 344,656 shares, compared to its average volume of 1,447,395. The stock has a 50 day moving average of $21.73 and a 200 day moving average of $20.86. Genmab A/S Sponsored ADR has a twelve month low of $17.24 and a twelve month high of $27.94. The firm has a market capitalization of $13.89 billion, a P/E ratio of 10.89, a PEG ratio of 6.35 and a beta of 0.95.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last announced its earnings results on Thursday, August 7th. The company reported $0.54 EPS for the quarter, beating the consensus estimate of $0.39 by $0.15. Genmab A/S had a return on equity of 21.03% and a net margin of 37.53%. The business had revenue of $925.00 million for the quarter, compared to analysts' expectations of $5.77 billion. Equities analysts expect that Genmab A/S Sponsored ADR will post 1.45 earnings per share for the current year.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.